ISRCTN94798326已完成未知
A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease
ational Cancer Institute of Canada Clinical Trials Group (NCIC CTG)0 个研究点目标入组 405 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 405
研究概览
简要总结
2012 results in: https://www.ncbi.nlm.nih.gov/pubmed/22149921 (added 17/05/2019)
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically proven Hodgkin's disease
- •2. Ann Arbor stage I-IIa disease
- •3. Age between 16 and 70 years
- •4. No prior chemotherapy or radiotherapy
- •5. No prior or concurrent malignancies, except treated basal cell carcinoma
- •6. No cardiac disease
- •7. No stage Ia disease which is treatable with involved field only irradiation
- •8. No interabdominal disease
- •9. No B symptoms
- •10. No known Human Immunodeficiency Virus (HIV) infection
排除标准
- •Not provided at time of registration.
研究者
相似试验
已完成
3 期
A Phase III study of radical radiotherapy with or without gemcitabine in patients with T1-2 N0-1 M0 non-small cell lung cancerung (non-small cell) cancerLung (non-small cell) cancerCancerISRCTN61727489niversity of Edinburgh (UK)
已完成
不适用
Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux® And CHemotherapy for unresectable carcinomas of head and necknresectable carcinomas of head and neckMalignant neoplasm of other and ill-defined sitesCancerISRCTN87356938niversity of Heidelberg (Germany)60
Unknown
2 期
Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung CancerStage III Non-small-cell Lung CancerNCT01576796Centre Henri Becquerel75
已完成
2 期
Radiotherapy with weekly gemcitabine (GEM)Bladder cancerCancerISRCTN64153246Christie Hospital NHS Foundation Trust (UK)50
已完成
3 期
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoMultiple sclerosisISRCTN70702834Genzyme Corporation (USA)700